Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR)
A Food and Drug Administration advisory panel will evaluate data on the oral drug, fidaxomicin. The medicine would be Optimer’s first product to reach the market if the FDA gives its approval.
Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (NYSE:CDI). In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.
Clostridium difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Illness from the bacterium most commonly affects older adults in hospitals or trin long term care facilities and typically occurs after use of antibiotic medications.( Read More http://crwepicks.com/?p=14925 )
For more information about this company please visit http://www.optimerpharma.com